The Rise of Virtual Care in Hematology and Oncology: A Comprehensive Review

By HEOR Staff Writer

September 11, 2023

The demand for continuous home and institutional care is escalating due to the ageing population and the increasing prevalence of chronic diseases. This demand is further amplified by the current context of limited professional resources. The COVID-19 pandemic has fast-tracked the deployment of virtual care tools, ensuring access to care and services while promoting continuity of care.

Virtual care modalities have been integrated into care pathways and are increasingly used in the evaluation, treatment, and follow-up of patients in specialty medicine, including haematology and oncology. These modalities have the potential to improve access to health care for most patients and foster their engagement in managing their illness.

A scoping review of scientific and grey literature conducted over the past five years by  the Institut national d’excellence en santé et en services sociaux (INESSS) has shed light on the care pathways that can be supported or optimised with the use of virtual care. Teleconsultation and tele-education have emerged as the most studied interventions in the care pathways of haematology and oncology.

The Potential and Concerns of Virtual Care in Oncology and Hematology

Despite the promising results, the number of studies exploring the efficacy of virtual care interventions in individuals with malignant or non-malignant homoeopathy remains limited. Similarly, few studies have investigated the impact of virtual care interventions according to the type of cancer, the disease stage, or the treatment protocol.

Virtual care modalities reported as having a positive impact include telemedicine, telehealth, e-health/mobile health, teleconsultation, tele intervention, and tele-education. Individuals with cancer or a hematologic disease, or cancer survivors, use these tools alone or in combination with other modalities to improve their quality of life and reduce their disease- and treatment-related symptoms.

Despite the potential benefits, some patients and health professionals have expressed concerns about the use of virtual care. These include worries about the ability to use new technology, problems with the technology, feeling distant and insecure, the lack of face-to-face contact and communication with health professionals, and the failure to recognize their signs of distress.

While the use of virtual care in haematology and oncology shows promise, more high-quality studies are necessary to fully understand its potential and address any concerns. As we continue to navigate the challenges posed by the COVID-19 pandemic, the role of virtual care in specialty medicine is likely to become increasingly important.

Reference url

Recent Posts

Navigating Novo Nordisk Board Changes: Leadership for Growth and Strategy

By João L. Carapinha

October 21, 2025

The Novo Nordisk board changes involve a major restructuring, as the Novo Nordisk Foundation is revitalizing leadership ahead of a general meeting on November 14, 2025, where new directors will be elected. Key candidates include former CEO Lars Rebien Sørensen as chair and Cees de Jong as vice ch...
Fabhalta Kidney Treatment Shows Promise in Slowing Disease Progression for IgA Nephropathy
Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline in patients with IgA nephropathy compared to placeb...
Keytruda Lung Cancer Treatment: Long-Term Survival Gains in NSCLC

By João L. Carapinha

October 20, 2025

If you're searching for effective options in Keytruda lung cancer treatment, recent data shows pembrolizumab (Keytruda) significantly boosts survival rates in non-small cell lung cancer (NSCLC). In the KEYNOTE-671 trial, this immunotherapy combined with chemotherapy raised five-year overall survi...